{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:30:04Z","timestamp":1786987804619,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ecl.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T03:47:15Z","timestamp":1753415235000},"page":"703-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathogenesis of Craniopharyngiomas and Targeted Approaches to Therapy"],"prefix":"10.1016","volume":"54","author":[{"given":"Simon","family":"Gritsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12 Suppl 2","key":"10.1016\/j.ecl.2025.06.006_bib1","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.ecl.2025.06.006_bib2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/neuonc\/nos142","article-title":"Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program","volume":"14","author":"Zacharia","year":"2012","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3171\/jns.1995.83.2.0206","article-title":"Papillary craniopharyngioma: a clinicopathological study of 48 cases","volume":"83","author":"Crotty","year":"1995","journal-title":"J Neurosurg"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.006_bib4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1469-8749.2004.tb00476.x","article-title":"Outcome of craniopharyngioma in children: long-term complications and quality of life","volume":"46","author":"Poretti","year":"2004","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.006_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2265.2005.02231.x","article-title":"Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00006123-200002000-00007","article-title":"Long-term outcomes for surgically resected craniopharyngiomas","volume":"46","author":"Duff","year":"2000","journal-title":"Neurosurgery"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.006_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1227\/00006123-199412000-00001","article-title":"Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome","volume":"35","author":"Weiner","year":"1994","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.006_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/nop\/npv029","article-title":"Multi-modality management of craniopharyngioma: a review of various treatments and their outcomes","volume":"3","author":"Varlotto","year":"2016","journal-title":"Neuro-Oncol Pract"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.006_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0360-3016(03)01570-0","article-title":"Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults","volume":"58","author":"Stripp","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.006_bib10","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/2010.1.FOCUS09307","article-title":"Craniopharyngioma: a comparison of tumor control with various treatment strategies","volume":"28","author":"Yang","year":"2010","journal-title":"Neurosurg Focus"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.006_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jocn.2010.10.004","article-title":"Management of recurrent craniopharyngioma","volume":"18","author":"Liubinas","year":"2011","journal-title":"J Clin Neurosci"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0360-3016(99)00030-9","article-title":"The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature","volume":"44","author":"Habrand","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.006_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0167-8140(93)90039-B","article-title":"Long-term results of pediatric and adult craniopharyngiomas treated with combined surgery and radiation","volume":"27","author":"Regine","year":"1993","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.006_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11060-012-0859-7","article-title":"Sleep dysfunction in long term survivors of craniopharyngioma","volume":"108","author":"Manley","year":"2012","journal-title":"J Neuro Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.radonc.2014.11.035","article-title":"Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma","volume":"114","author":"Greenfield","year":"2015","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.006_bib17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/S0002-9440(10)64477-X","article-title":"Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations","volume":"161","author":"Sekine","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ecl.2025.06.006_bib18","series-title":"IARC WHO Classification of Tumours","first-page":"1","article-title":"WHO classification of tumours of the central nervous system","volume":"1","year":"2016"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.006_bib19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/EJE-15-0709","article-title":"History before diagnosis in childhood craniopharyngioma: associations with initial presentation and long-term prognosis","volume":"173","author":"Hoffmann","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"28","key":"10.1016\/j.ecl.2025.06.006_bib20","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.1073\/pnas.1101553108","article-title":"Increased Wingless (Wnt) signaling in pituitary progenitor\/stem cells gives rise to pituitary tumors in mice and humans","volume":"108","author":"Gaston-Massuet","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.006_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-006-0184-3","article-title":"Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas","volume":"113","author":"Buslei","year":"2007","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/jcm9020519","article-title":"The inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment","volume":"9","author":"Whelan","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.006_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12964-021-00797-w","article-title":"CBX4-dependent regulation of HDAC3 nuclear translocation reduces Bmp2-induced osteoblastic differentiation and calcification in adamantinomatous craniopharyngioma","volume":"20","author":"Yan","year":"2022","journal-title":"Cell Commun Signal"},{"issue":"7","key":"10.1016\/j.ecl.2025.06.006_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/a-0593-5956","article-title":"Impact of the canonical Wnt pathway activation on the pathogenesis and prognosis of adamantinomatous craniopharyngiomas","volume":"50","author":"Juc\u00e1","year":"2018","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.006_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.006_bib26","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1007\/s00018-021-03798-7","article-title":"Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis","volume":"78","author":"Gonzalez-Meljem","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.006_bib27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3171\/2015.7.PEDS14449","article-title":"Growth patterns of craniopharyngiomas: clinical analysis of 226 patients","volume":"17","author":"Pan","year":"2016","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.ecl.2025.06.006_bib28","series-title":"WHO Classification of Tumours Series","first-page":"1","article-title":"WHO classification of tumours eeditorial board. Central nervous system tumours","volume":"6","year":"2021"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib29","first-page":"126","article-title":"Genomic alterations of adamantinomatous and papillary craniopharyngioma","volume":"76","author":"Goschzik","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.006_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00401-014-1270-6","article-title":"BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma","volume":"127","author":"Larkin","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.006_bib31","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3390\/curroncol29030138","article-title":"Current advances in the management of adult craniopharyngiomas","volume":"29","author":"Lara-Velazquez","year":"2022","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.006_bib32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/pbc.25889","article-title":"A cross-sectional cohort study of cerebrovascular disease and late effects after radiation therapy for craniopharyngioma: CVD after RT in craniopharyngioma","volume":"63","author":"Lo","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.006_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clon.2018.01.012","article-title":"Proton therapy for craniopharyngioma - an early report from a single European centre","volume":"30","author":"Ajithkumar","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib34","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.ijrobp.2016.06.294","article-title":"Necrosis, vasculopathy, and neurological complications after proton therapy for childhood craniopharyngioma: results from a prospective trial and a photon cohort comparison","volume":"96","author":"Merchant","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.006_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1470-2045(23)00146-8","article-title":"Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR): a single-arm, phase 2 study","volume":"24","author":"Merchant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.006_bib36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1227\/NEU.0b013e31826d5c31","article-title":"Intracystic bleomycin for cystic craniopharyngiomas in children (abridged republication of cochrane systematic review)","volume":"71","author":"Liu","year":"2012","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib37","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.ecl.2025.06.006_bib38","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ecl.2025.06.006_bib40","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2025.06.006_bib41","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2025.06.006_bib42","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ecl.2025.06.006_bib43","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Rostami","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Roque","year":"2017","journal-title":"CNS Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.006_bib45","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report","volume":"130","author":"Himes","year":"2019","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.006_bib46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/neuros\/nyy569","article-title":"A clinical rule for preoperative prediction of BRAF mutation status in craniopharyngiomas","volume":"85","author":"Fujio","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ecl.2025.06.006_bib47","article-title":"Application of artificial intelligence in diagnosis of craniopharyngioma","volume":"12","author":"Qin","year":"2021","journal-title":"Front Neurol"},{"issue":"24","key":"10.1016\/j.ecl.2025.06.006_bib48","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.3390\/jcm11247481","article-title":"Pathological diagnosis of adult craniopharyngioma on MR images: an automated end-to-end approach based on deep neural networks requiring no manual segmentation","volume":"11","author":"Teng","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ecl.2025.06.006_bib49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","article-title":"Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors","volume":"62","author":"Krishnamurthy","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.006_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28753","article-title":"Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ecl.2025.06.006_bib51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3389\/fonc.2019.00791","article-title":"Targeting IL-6 is a potential treatment for primary cystic craniopharyngioma","volume":"9","author":"Grob","year":"2019","journal-title":"Front Oncol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:33:29Z","timestamp":1761147209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0889852925000726"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.06.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis of Craniopharyngiomas and Targeted Approaches to Therapy","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}